Desoximetasone

Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 203787, held by Sciegen Pharms. Desoximetasone.

As of Nov 15, 2026, ANDA 203787 (Desoximetasone), held by Sciegen Pharms, was first approved by FDA on Jan 6, 2017, with 1 approved supplement and 0 published complete response letters.

First approved: Jan 6, 2017
Supplements approved: 1
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

INDICATIONS AND USAGE Desoximetasone cream, USP 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 2 submissions below

Date	Submission	Status	Documents
Jan 6, 2017	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Desoximetasone0.05% · cream;topical	Desoximetasone	Rx

All 2 submissions, including labeling and manufacturing supplements


Mar 16, 2026	Supplement 2Manufacturing	Approved	None posted
Jan 6, 2017	Original application	Approved	None posted

Identifiers

Application: ANDA 203787
Drugs@FDA: Overview at FDA
Company: ScieGen Pharmaceuticals

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters